Haifeng Cui

Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors

Krista Goodman, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 154 citations · Full text

Indazole Substitution, Medicinal Chemistry, Oral Bioavailability +11

Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin

Pan F. Chan, Srikannathasan Velupillai, Jianzhong Huang et al. · Nature Communications · 2015 · 153 citations · Full text

Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase

Pan F. Chan, Thomas Germe, B.D. Bax et al. · Proceedings of the National Academy of Sciences · 2017 · 84 citations · Full text

Bioorganic Chemistry, Molecular Biology, Thiophene Inhibitors +17

Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

Robert A. Stavenger, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 71 citations · Full text

Drug Target, Bioorganic Chemistry, Pharmacotherapy +18

Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors

Steven T. Staben, Jianwen A. Feng, Karen S. Lyle et al. · Journal of Medicinal Chemistry · 2014 · 63 citations · Full text

Compound 17, Structure-based Methods, Kinase Inhibitors +18